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Abstract
Background: The seed and soil hypothesis was proposed over a century ago to describe why cancer cells (seeds)
grow in certain organs (soil). Since then, the genetic properties that define the cancer cells have been heavily
investigated; however, genomic mediators within the organ microenvironment that mediate successful metastatic
growth are less understood. These studies sought to identify cancer- and organ-specific genomic programs that
mediate metastasis.
Methods: In these studies, a set of 14 human breast cancer patient-derived xenograft (PDX) metastasis models was
developed and then tested for metastatic tropism with two approaches: spontaneous metastases from mammary
tumors and intravenous injection of PDX cells. The transcriptomes of the cancer cells when growing as tumors or
metastases were separated from the transcriptomes of the microenvironment via species-specific separation of the
genomes. Drug treatment of PDX spheroids was performed to determine if genes activated in metastases may
identify targetable mediators of viability.
Results: The experimental approaches that generated metastases in PDX models were identified. RNA sequencing of
134 tumors, metastases, and normal non-metastatic organs identified cancer- and organ-specific genomic properties
that mediated metastasis. A common genomic response of the liver microenvironment was found to occur in reaction
to the invading PDX cells. Genes within the cancer cells were found to be either transiently regulated by the
microenvironment or permanently altered due to clonal selection of metastatic sublines. Gene Set Enrichment
Analyses identified more than 400 gene signatures that were commonly activated in metastases across basal-
like PDXs. A Src signaling signature was found to be extensively upregulated in metastases, and Src inhibitors
were found to be cytotoxic to PDX spheroids.
Conclusions: These studies identified that during the growth of breast cancer metastases, there were genomic changes
that occurred within both the cancer cells and the organ microenvironment. We hypothesize that pathways upregulated
in metastases are mediators of viability and that simultaneously targeting changes within different cancer cell pathways
and/or different tissue compartments may be needed for inhibition of disease progression.
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Background
It is well accepted that there are many different breast
cancer subtypes, which have a wide range of prognoses
[1–5]. Nearly all patients that die from breast cancer
succumb to the disease due to the expansive growth of
metastatic cells within vital organs. The spread of cancer
cells away from the primary tumor depends on their
ability to intravasate into the vasculature, survive in the
circulation, extravasate into a foreign tissue microenvir-
onment, and proliferate into a secondary mass. These
properties are variable across different breast cancer
subtypes, which give rise to different metastatic organ
distributions, expansive latencies, and overall survival
outcomes [6].
Knowledge of each phase of the metastatic cascade has
dramatically increased over the past 20 years. Breast tu-
mors do not need to form an overt mass prior to dis-
semination, and often, metastases have already spread to
vital organs at the time of initial primary tumor diagno-
sis [7]. Triple-negative breast cancer (TNBC) cells can
perform vascular mimicry, interdigitate within endothe-
lial cells, and spread very early in the development of a
malignant lesion [8–10]. Once in the lymphatic or blood
vascular circulation, the cells can travel as single cells or
emboli which may or may not result in clonal or poly-
clonal secondary metastatic tumors. Successful meta-
static extravasation into vital organs is a rate-limiting
step for many cancer cells [11] and does occur in each
subtype of breast cancer. The biological mechanisms
that promote successful metastatic expansion are found
within the cancer cells and facilitative organ microenvir-
onment. A better understanding of how different meta-
static microenvironments contribute to the expansion of
micro-metastases into macro-metastases will allow more
specific targeting of the microenvironment to prevent
the expansion of metastatic disease.
To elucidate cell-specific gene expression in metastases,
previous studies have performed laser capture microdis-
section of frozen tissue sections, or antibody-based cell
sorting of live cells, followed by gene expression analyses
[12, 13]. Alternatively, human and mouse-specific gene ex-
pression microarrays have been used on xenografts de-
rived from cancer cell lines [14, 15]. Bioinformatic
analyses of sorted tumor samples, or bulk tissues from pa-
tients or transgenic mouse models, have identified that
the majority of cancer-driving mutations and DNA copy
number changes are present in the primary tumor and
largely maintained throughout disease progression [5]. It
is now important to develop RNA sequencing datasets
and analysis pipelines to more accurately define both can-
cer and microenvironmental contributors to metastatic
colonization. In these studies, we focus on characterizing
the metastatic properties of 14 distinct patient-derived xe-
nografts (PDX) that represent estrogen receptor (ER)
positive, TNBC, and human epidermal growth factor
receptor 2 (HER2)-positive disease. Given the lack of
treatment options for TNBC, we primarily focus on un-
derstanding the mechanisms used by these cells to grow
in the liver and lung. Interestingly, a set of common gen-
etic signatures was identified as being upregulated in mul-
tiple basal-like metastases, targeting the most upregulated
pathway with FDA-approved drugs reduced cancer cell
viability when tested on PDX spheroids. In addition, an in-
flammatory response genomic program was upregulated
by the liver microenvironment in response to the invading
cancer cells. We hypothesize that this information can be
used to help develop metastasis-targeted therapeutics to
inhibit the growth of disseminated cells.
Methods
Development of PDX metastasis models
PDX models were obtained through material transfer
agreements with Washington University in Saint Louis
(WHIM2, WHIM30), the University of Utah/Huntsman
Cancer Institute (HCI01, 02, 03, 04, 08, 09, 10, 11, 13, 16),
and the University of Colorado (UCD18, UCD52). After
successful growth of the PDX cells or tumor fragments in
the fourth mammary fat pad of non-obese diabetic severe
combined immunodeficiency (NOD-SCID-gamma/NSG)
mice, tumors were collected and digested into a single-cell
suspension as described previously [16, 17] and then incu-
bated with lentivirus encoding for green fluorescent pro-
tein and luciferase (GFP+Luc) (BLIV101PA-1; Systems
Biosciences). After selection of the transduced cells with
flow cytometry, the cells were serially passaged in the
mammary gland. All experiments utilized 500,000 cancer
cells to initiate mammary tumors or metastases. Through-
out the in vivo studies that investigate rate and location of
metastases, mice were routinely imaged using an IVIS
Spectrum In Vivo Imaging System (IVIS200), after injec-
tion of D-luciferin (15mg/ml) (Gold Biotechnology). Me-
tastases were quantified with ex vivo imaging of each
organ at necropsy. Sites of relapse of the PDX tumors
were compared with previous publications or from per-
sonal communications with Dr. Alana Welm.
Immunohistochemistry and immunofluorescence
To determine standard clinical biomarker status for the
PDXs, mammary tumors were fixed in 10% formalin
overnight, paraffin-embedded, and cut into 6-μm sec-
tions. Slides were subjected to heat-induced epitope re-
trieval with a pressure cooker in pH 9 Tris-EDTA
buffer. Antibodies used were from the following:
Abcam: estrogen receptor (ER) (SP1 ab16660); Biole-
gend: Alexa Fluor 488 Cytokeratin (628608) and Alexa
Fluor 594 Vimentin (677804); Cell Signaling Technol-
ogy: HER2 (2242), Ki67 (D2H10), PR (8757), S100A9
(73425), and Vimentin (D21H3); ThermoFisher:
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Cytokeratin (PA1-27114); Millipore: LCN2 (AB2267);
and Novus: SMA (NB600-531). Antibodies used for im-
munohistochemistry were incubated overnight at 4 °C
and combined with the DAKO EnVision rabbit second-
ary antibody kit. All images were collected with a Zeiss
AxioLab upright microscope and Zeiss AxioCam ICc 5,
and Zen2 software.
RNA sequencing and availability of data
Tissues were flash frozen, and RNA was prepared with
the Qiagen RNeasy mini kit. The KAPA Stranded
mRNA-Seq kit was used for library preparation, and
samples were sequenced on the Illumina Hi-Seq 2500
according to Illumina sequencing-by-synthesis protocol.
One hundred twenty-five-base pair paired-end reads
were generated, yielding on average 42M reads per sam-
ple. The dataset supporting the conclusions of this article
are available in the NCBI Gene Expression Omnibus
(GEO Accession GSE118942). All library preparations and
sequencing were performed by the Brigham Young Uni-
versity DNA Sequencing Core. Reads were aligned to a
custom concatenated reference genome consisting of hu-
man, mouse, and viral genomes. The GRCh38 human
genome that includes viral sequences (GRCh38.d1.vd1.fa.-
tar.gz) was retrieved from NCI’s Genomic Data Commons
at https://gdc.cancer.gov on January 3, 2017. The corre-
sponding annotation file (gencode.v22.annotation.gtf.gz)
was downloaded from the same site on 1/4/17. The
GRCm38 M12 Gencode release, primary assembly mouse
genome was retrieved from http://www.gencodegenes.org
on January 3, 2017 along with the corresponding pri-
mary assembly annotation file from the same site on
January 4, 2017. Finally, the genome of Xenotropic
murine leukemia virus (XMLV) (accession
#JF274252.1) was downloaded from NCBI’s Nucleotide
database, https://www.ncbi.nlm.nih.gov on February
28, 2017. Chromosomes were labeled with
organism-specific prefixes before concatenation in a
similar fashion to the method described by Callari et
al. [18], which recently reported custom concatenated
reference genomes to outperform other methods in
classifying RNA from different species in PDX
models.
RNA-Seq pre-processing and quality control
FastQC v.0.11.5 [19] was used for quality control. STAR
v2.5.2b [20] was used to index the concatenated refer-
ence genome prior to alignment. The FASTQ files were
aligned to the concatenated genome using STAR with
the following parameter settings: --outSAMtype BAM
Unsorted --outSAMorder Paired --outReadsUnmapped
Fastx --quantMode TranscriptomeSAM --outFilterMul-
timapNmax 1. The number of unmapped reads and
reads mapped to human, mouse, and viral genomes were
obtained through an in-house bash script utilizing SAM-
Tools v1.3.1 [21]. Human and mouse percentages were
calculated using the total number of reads aligned to hu-
man or mouse only, and do not include unmapped reads
or reads aligned to viral genomes. Read counting to ob-
tain gene expression values from the aligned BAM files
utilized a transcript reference file created from the
concatenated genome and was performed using the Sal-
mon v0.8.2 “quant” algorithm [22] with the library type
set to “IU.” The counts were imported into R v.3.4.0
using the tximport [23] R package v.1.4.0. Transcripts
per million (TPM) expression values were calculated
using human and mouse transcript counts separately.
This effectively normalizes the gene expression by the
varying percent of human and mouse genomic content.
Log2-transformed TPM values were used for all analyses
except the PAM50 subtyping, which used unlogged
TPM values. Genes were filtered to remove those with a
Log2 TPM of zero across all samples. Quality control
steps were taken to ensure data integrity before and after
alignment. Evaluating the number of reads sequenced in
each FASTQ file revealed several samples that had fewer
than 15 million sequenced reads. These files were
re-sequenced, and resulting data from the two runs were
merged as BAM files after alignment using SAMTools
v1.3.1 merge function (Additional file 1) indicates which
files were run a second time. The merged BAM files
were then utilized in the rest of the pipeline for these
samples. A second quality control step utilized Pearson’s
correlation of the Log2 TPM expression profiles for all
sample pairs. This revealed two samples that clustered
unexpectedly with different cell lines where the expres-
sion profiles were clearly different from the labeled cell
type. Upon further investigation, it was found these sam-
ples were right next to each other in the tray and the la-
bels were accidentally swapped. For all analyses, these
sample labels are corrected to refer to the correct cell
type.
PAM50 subtype classification
Prior to subtyping, the PDX samples were filtered to
those with more than 10 million mapped human reads,
which resulted in 101 samples for subtyping. PAM50
subtypes were identified for each sample from the TPM
values using the “molecular.subtyping” function of the
genefu v2.11.2 package [24] in R with the “sbt.model” set
to “pam50”.
TCGA/PDX integration
Gene expression for TCGA-BRCA samples was obtained
via the TCGABioLinks v2.5.9 Bioconductor R package [25]
using the GDCquery function with the following settings:
project = c(“TCGA-BRCA”), file.type = “rsem.genes.results”,
platform= “Illumina HiSeq”, legacy = TRUE, sample.type=“
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Primary solid Tumor”, data.category = “Gene expression”,
data.type = “Gene expression quantification”, experimental.-
strategy = “RNA-Seq”. The RSEM scaled estimates were
converted to Log2 TPM values as described in Li et al. [26].
PAM50 subtypes for each TCGA patient were obtained
from Ciriello et al. [3] resulting in a list of 817 patients from
the TCGA data with a PAM50 subtype. Filtering the PDX
samples to remove all normal mouse samples and all sam-
ples with less than 10 million human reads left 101 PDX
samples for integration with TCGA data. The Log2 TPM
values of the TCGA and PDX cohorts were merged, and
the data matrix was filtered to contain expression for the
PAM50 genes. Gene expression values were then upper
quantile normalized and row-median centered prior to
clustering. Merged TCGA/PDX data were clustered using
the ComplexHeatmap v1.14.0 package [27] in R with Pear-
son’s correlation as the distance metric and ward.D2 as the
linkage method.
Differential expression analysis
All differential gene expression analyses were done using
the DESeq2 v1.16.1 R package with raw read counts as
input. Prior to DESeq2 analysis, genes with zero expres-
sion across all samples were removed, and only genes
having average expression larger than 0.5 in at least 10%
of the samples and with the ratio of maximal/minimal
intensity larger than 0.5 were kept. This resulted in a
lower number of genes for analysis by DESeq2, which
reduced multiple testing correction burden and analysis
time. The exact number of genes considered by DESeq2
after gene filtering varied depending on the samples in-
cluded in the contrast. Gene expressions were adjusted
by percent of human or mouse aligned reads by includ-
ing the appropriate percentage in the DESeq2 dataset
design formula as “~ percent+condition”, where “per-
cent” was the human or mouse percent of mapped reads
(mouse percent was used when calculating mouse ex-
pression and human percent when calculating human
expression), and “condition” is the sample condition
(e.g., MGT, Met, Normal). A Benjamini-Hochberg ad-
justed p value of 0.05 or less was used as the threshold
for determining a significant differentially expressed
gene. For all tables, the “NA” values in the padj column
indicate DESeq2 filtered these genes out of the multiple
testing correction due to a low-base mean value and/or
outlier values. baseMean is the normalized average read
count across all samples in contrast. log2FoldChange is
the Log2 of the calculated fold change.
Principal component analysis
PCA was run using the prcomp function on the cen-
tered and scaled, upper quantile normalized Log2 TPM
expression profiles for the 2000 most variable genes for
a subset of PDX samples. This subset includes one
representative sample from each cell type chosen based
on the highest human transcript abundance. The PCA
plot was generated using ggplot2 v3.0.0 and ggrepel
v0.8.0 R packages [28, 29].
Mouse RNA-seq expression clustering
The variance in the upper quantile normalized, Log2
TPM mouse gene expression across 42 PDX samples
with greater than 50% mouse mapped reads was calcu-
lated using R’s “var” function. Hierarchical clustering of
the row-median centered top 2000 most variable genes
using Pearson’s correlation as the distance metric and
ward.D2 as the linkage method was performed by R’s
ComplexHeatmap package.
ANOVA of gene expression data
TPM values from the human or mouse RNA-seq data
presented herein, normalized mRNA counts from sup-
plemental Table 7 from Siegel et al. [30], or gene expres-
sion data from Tobin et al. [31] were subjected to
analysis of variance in R.
Gene Set Enrichment Analyses
Single-sample Gene Set Enrichment Analysis (ssGSEA)
was performed using the GSVA R package v.1.30.0 [32]
separately for human and mouse gene expression data-
sets. Briefly, samples with > 50% of human (or mouse)
reads were selected. The Log2-transformed TPM values
were used to rank transcripts for ssGSEA analysis. The
MSigDB v.5.2 [33] [34] data (> 18,000 gene signatures,
https://github.com/stephenturner/msigdf ) was used. En-
richment scores were clustered using Cluster 3.0 [35]
and visualized using Java TreeView v.1.1.6 [36]. Differ-
ences in enrichment scores comparing average values of
gene sets in mammary tumors versus metastases were
calculated; the differences in average enrichment scores
between mammary tumors and metastases were then
combined to rank order the gene sets that were most
highly upregulated in metastases across all six basal-like
PDXs.
Treatment of PDX spheroids in suspension culture
At least three different mammary tumors from seven dis-
tinct PDXs were collected, digested into a single-cell sus-
pension as described previously [16, 17] and then plated
in M87 medium. Saracatinib, bosutinib, and dasatinib
were purchased from ApexBio and used at 10 μM for 72-h
cytotoxicity assays. Cell viability was quantified using
luciferase-based imaging, and viability of drug-treated cells
was compared to that of vehicle-treated cells. All assays
were performed as at least three biological replicates in
triplicate.
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Results
PDX metastasis models
The schematic in Fig. 1 provides an overview of the de-
velopment of the PDX models and highlights how they
were utilized for the studies presented herein. In total,
14 different breast cancer PDXs were transduced with
lentiviral particles encoding for green fluorescent protein
and luciferase (GFP+Luc): UCD18, UCD52, WHIM2,
WHIM30, HCI01, HCI02, HCI03, HCI04, HCI08,
HCI09, HCI10, HCI11, HCI13, and HCI16. After
expansion in vivo, the GFP+ populations were collected
through fluorescence-activated cell sorting, injected into
the mammary glands of donor mice, and then expanded
and maintained through serial passaging in the mam-
mary gland. Immunohistochemistry for ER, PR, and
HER2 was performed on mammary tumors for each
PDX (Additional file 2). Three of the PDXs were ER+
and progesterone receptor positive (PR+) (HCI03,
HCI11, HCI13), whereas the rest were ER−/PR−. HCI08,
and, to a lesser extent, HCI04, expressed HER2 (Table 1).
Fig. 1 Schematic of experimental approach used to identify genomic mediators of patient-derived xenograft metastases. PDX tumors were
grown in the mammary gland, extracted and digested into single-cell suspensions, and then labeled with lentivirus that encoded for green
fluorescent protein and luciferase (GFP + Luc). After expansion in vivo, the cells with the brightest GFP were expanded in the orthotopic location,
then used for metastasis studies. Paired-end RNA sequencing was then performed on mammary tumors, normal tissues, and brain, lung, and liver
metastases. The sequencing data was then aligned to both the mouse and human reference genomes
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The mammary gland growth rate of each PDX was
found to be highly variable and did not correlate with
ER status (Fig. 2a).
Spontaneous metastases from mammary tumors
Several different experimental approaches were used to
generate metastases that could be analyzed with RNA
sequencing. First, unilateral mammary tumors from the
14 PDXs were grown and spontaneous metastases
tracked with luciferase imaging. To mimic the clinical
condition, survival surgeries were performed to remove
primary tumors once they were 1–1.3 cm in diameter,
and then mice were monitored for up to 120 days to de-
tect metastases. At the time of surgical tumor removal,
two of the PDXs had observable lymph node metastases
(HCI09, HCI10). Following surgery, mice were imaged
weekly for up to 16 weeks, or until moribund due to me-
tastases. At necropsy, there was a wide variance in the
organs that were colonized by the PDXs, with the excep-
tion being that all PDXs that generated metastases suc-
cessfully seeded the lung and may also spread to the
axillary lymph node on the same side of the mouse
where the tumor was growing (Fig. 2b). Interestingly,
though several PDXs effectively seeded the liver, they did
not generate macro-metastases in the timeframe ob-
served (WHIM2, HCI09). In contrast, WHIM30 and
HCI10 liver metastases were large and multifocal. Brain
and ovary metastases were also observed in some
PDXs. Bone metastases were not routinely assessed in
all models. Several models were not metastatic (UCD18
(n = 9), HCI04 (n = 4), and HCI16 (n = 5)).
Metastases from systemic injections
Tail-vein injections of PDX cells were performed as a
second measure of metastatic ability. As expected, the
greatest overall difference between the two experimental
approaches was that the axillary lymph node, which
drains the abdominal mammary gland, had significantly
fewer metastases in tail-vein injected mice. In contrast,
liver and ovary metastases were more frequent after
tail-vein injection (Fig. 2c). The same PDXs which failed
to produce spontaneous metastases from primary tu-
mors also failed to generated metastases from tail-vein
injections (n > 3). Since spontaneous metastases from
mammary tumors and tail-vein injections failed to yield
consistent brain metastases, we performed intracardiac
injections as this approach has been shown to yield cere-
bral metastases in other studies [37–39]. Successful in-
jections of either WHIM2 or WHIM30 yielded brain
metastases in 100% of the mice (Additional file 3). Com-
paring the patient data from which the PDX samples
were derived, the PDX experiments and the organs in
which metastases were found were similar; interestingly,
the HCI04 PDX did not generate metastases and none
were observed in the patient (Additional file 4).
Serial passaging of metastases to heighten organ tropism
We sought to generate PDX models that were more
overtly metastatic to the liver. Liver metastases were
generated via liver parenchymal injections or portal vein
injections with WHIM2, WHIM30, HCI10, and UCD52,
and then serially passaged through multiple rounds of
selection in the liver. Similar to a previous report with
PDXs [40], the majority of the PDXs did not become
more metastatic, except for UCD52, which resulted in
liver tropic cells (UCD52-M) that homed to the liver in
90% of tail-vein injected mice, as compared to 0% of the
parental PDX (Fig. 2c, Additional file 5). Spontaneous
metastases from UCD52-M mammary tumors after re-
section were not thoroughly assessed.
PDX metastasis RNA sequencing dataset
To determine the extent to which the cancer cell tran-
scriptome, or organ transcriptome, changed when the
cells were growing in the mammary gland, or as liver or
lung metastases, RNA sequencing was performed on a
set of 119 PDX mammary tumors and metastases, and
normal mouse organs (3 replicates each of brain, liver,
and lung). Six patient samples were also included as
pure human sample controls. Given the relative lack of
data on liver metastases as compared to metastases to
the brain or lung, emphasis was placed on sampling dis-
seminated cells in the liver, and only TNBC metastases
were sequenced. Since the mouse and human genomes
differ in their RNA sequences, we used these sequence
differences to computationally separate the mouse and
Table 1 IHC characteristics and intrinsic subtype of the PDX
lines
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human genomes from each sample to generate a
“mouse dataset” and a “human dataset.” Figure 3a
shows the distribution of mouse and human content
in the 134 samples; dataset characteristics are pre-
sented in Additional file 1. The mammary gland tu-
mors (MGT) were 72–91% human, whereas
metastases to the brain, liver, and lung exhibited a
very large range in the amount of human RNA per
sample; brain (0.12–84%), liver (0.94–91%), and lung
(2–90%), which is likely due to the amount of normal
adjacent mouse tissue within the specimen. To deter-
mine the genomic relationships between each mam-
mary tumor PDX, a principal component analysis was
performed on the 2000 most variable genes; the tu-
mors segregate based largely on their PAM50-defined
intrinsic subtype [41]. As expected, the two ER+
PDXs that were sequenced, HCI03 and HCI13, were
similar to each other and distinct from the basal-like
TNBC, except for HCI09, which has been classified
previously as histologically TNBC, but genetically lu-
minal B [42] (Fig. 3b). Next, the mouse dataset was
hierarchically clustered using the 2000 most variable
genes from the metastases and normal mouse tissue.
As expected, the lung, liver, and brain transcripts sep-
arated from each other, with some variability arising
in some of the tissues harboring metastases (Fig. 3c). To
determine if these models were representative of human
patient samples, the human transcripts from the PDX data
were merged with 817 TCGA breast cancer samples using
a similar methodology as presented in Sachs et al. [43].
These data showed that the ER+ PDX integrate within the
luminal TCGA samples, the HER2+ HCI08 was related to
HER2-Enriched samples, and the TNBC/basal-like PDX
samples had genomic profiles similar to the basal-like
samples (Fig. 3d).
Effect of microenvironment on gene expression
To determine if the cancer and microenvironment data-
sets had been properly segregated, genes that were differ-
entially expressed were validated by immunofluorescence
or immunohistochemistry (Fig. 4). For the human dataset,
vimentin expression was found to be variable across four
TNBC PDX mammary tumors at the RNA level (Fig. 4a).
Immunofluorescence of tumor sections for vimentin and
pan-cytokeratin was congruent with the RNA-level data
(Fig. 4b). HCI09 did not express vimentin other than the
supporting fibroblasts, whereas UCD18 was found to have
cells that expressed either cytokeratin or vimentin. HCI01
and HCI10 co-expressed both proteins in most of the
tumor cells. Analysis of normal and metastatic liver
a
b c
Fig. 2 Assessment of tumor growth rates and metastatic distributions of 14 breast cancer PDXs. a Cancer cells were injected into the abdominal
mammary gland and measured weekly for tumor growth. ER+ and HER2+ PDXs are designated, all the others are TNBC. b Quantification
of spontaneous metastases after surgical excision of primary tumors. c Quantification of metastases from after tail-vein injection of PDX cells
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samples from the mouse dataset, which represent the liver
microenvironment, focused on known tissue microenvir-
onment proteins S100a9, Acta2 (smooth muscle actin),
and Lcn2 (Fig. 4c); all three of these transcripts were up-
regulated during metastatic growth in the liver. Immuno-
histochemistry for S100a9, which has been shown to be a
marker for neutrophils [44], found that S100a9+ cells were
often surrounding metastatic lesions in the liver, but were
rarely within the bulk of the metastases. Acta2 was dra-
matically upregulated at the RNA and protein levels and
identified fibroblasts that become activated within
expanding liver metastases. Lcn2-positive cells were ob-
served in peri-tumor areas of liver metastases.
Having confidence that the virtual dissection of cancer
and microenvironment was performed properly, DESeq2
was utilized to identify genes differentially expressed in
seven different TNBC PDXs when growing as a liver
metastasis as compared to a mammary tumor
(Additional file 6). The majority of PDXs had between 33
and 295 genes significantly upregulated and 5 to 393 sig-
nificantly downregulated (p < 0.01) in the liver metastases
as compared to the mammary tumor; in contrast, the
UCD52 PDX that was serially passaged in the liver
(UCD52) had more than 2000 genes significantly in-
creased or decreased compared to the parental mammary
tumor. Shown in Additional file 7a are 18 genes that were
upregulated at least twofold in liver metastases compared
to mammary tumors in 5 of the 7 TNBC PDXs. Ingenuity
Pathway Analysis (IPA) revealed that many of these genes
are known to interact and be associated with cancer
(Additional file 7b). In contrast to the cancer cell genomic
data, when the liver microenvironment was colonized,
there was a uniform and significant genomic response by
the host organ to each of the PDXs; 27 genes were signifi-
cantly upregulated in the mouse liver of every PDX
(Additional file 7c). IPA analyses of these 27 genes (the
liver microenvironment-induced gene signature) revealed
that their top biological function is as mediators of the
Fig. 3 Virtual dissection of PDX mammary tumors and metastases into cancer (human) and microenvironment (mouse) gene expression datasets.
The 134 sample RNA-sequencing dataset; PDX mammary tumors and metastases to the brain, lung, and liver; normal mouse brain, lung, and liver;
100% human breast tumors and brain metastases. a The transcripts from the 134 samples were segregated into human and mouse datasets;
shown is the percent of each genome within each sample. b One mammary tumor from each PDX line was used in a Principal Component
Analysis based on the 2000 most variable genes. c Mouse transcripts from metastases to the brain, lung, and liver, as well as normal mouse brain,
lung, liver, were used to cluster the mouse genome based on the most variable top 2000 genes. d PDX tumors and metastases with more than
ten million human mapped transcripts were combined with RNA-seq data from 817 tumors from The Cancer Genome Atlas. The PAM50 genes
were used to hierarchical cluster the combined dataset
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inflammatory response (Additional file 7d). The genes up-
regulated in the mouse liver genome in response to PDX
cells are shown in Additional file 8.
A more limited approach was taken to investigate
the genes which were dynamically expressed in lung
metastases. When comparing mammary tumors and
lung metastases from three TNBC PDXs, similar
trends were observed as with the liver analyses, with
different magnitudes of gene expression being
observed across the PDXs (Additional file 9 and
Additional file 10). Interestingly, only two human
genes were found to be upregulated in most liver me-
tastases and lung metastases: A2M and ST3GAL5.
For the mouse lung genomic response to metastatic
growth, there were 3656 genes upregulated more than
twofold in 2 of 3 PDX lung metastases (Additional file 11).
In contrast to the few common human genomic
changes in liver and lung metastases, there were 299
transcripts similarly upregulated in mouse liver and
lung RNA, which were likely in part due to transi-
tionary neutrophils and macrophages. Overall, across
all the PDXs tested, the liver genomic response to the
invading cancer cells was more robust and consistent
than that of the lung.
Separation of liver-expressed transcripts from human
metastasis gene signatures
The next goal was to determine if this data could be
used to distinguish cancer and organ-specific genes from
metastasis biopsies. To identify genes that were differen-
tially expressed in matched tumors and metastases, Sie-
gel et al. [30] compared the DNA and RNA of primary
breast tumors and their matched metastases from aut-
opsy samples and identified a set of genes that were dif-
ferentially expressed in each tumor-metastasis pair; 171
genes were increased in metastases (Fig. 5a). We tested
the 171 genes to identify those that were likely arising
from the liver microenvironment. Analysis of variance
tests on the mouse RNA-seq dataset, comparing PDX
liver metastases with normal mouse liver, revealed that
24 of the 171 genes were significantly (p < 0.05) upregu-
lated in the liver transcriptome from the PDX samples
(Fig. 5b), suggesting these genes might be derived from
the liver microenvironment in response to cancer
growth. Analysis of a second dataset of human breast
cancer fine-needle aspirates (FNA) from liver or breast
relapses [31] found that the activated liver microenviron-
ment signature shown in Additional file 7c was signifi-




Fig. 4 Validation of human and mouse-specific transcripts with immunofluorescence microscopy and immunohistochemistry. a Box and whisker
plots showing human vimentin RNA expression levels in TNBC mammary tumors. b Immunofluorescence microscopy for pan-cytokeratin (green),
vimentin (red), and DAPI (blue) in TNBC mammary tumors. c The mouse RNA-seq dataset was queried for genes that were differentially expressed
in normal mouse liver as compared to mouse livers colonized by metastatic cells. Immunohistochemistry of liver metastases to validate
the increased RNA expression observed in liver metastases. Asterisk denotes the location of cancer cells; arrows denote S100a9 cells in the peri-tumor
area surrounding the cancer cells
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in FNA samples, contributions of the microenvironment
genome can be identified.
Distinguishing clonal selection of metastatic cells and
microenvironment-induced temporary genomic changes
in cancer cells
To determine the pathways that were permanently al-
tered, or selected for, during metastasis, as compared to
the genes that were temporarily increased in the cancer
cells due to the liver or lung microenvironment, sets of
metastases were collected and transplanted back into the
mammary gland (Fig. 6a). Triads of tumors (i.e.,
mammary tumors, metastases, and mammary tumors
from metastases) were RNA-sequenced and compared.
Microenvironment-induced plasticity was observed in
some genes, such as Id1, that were upregulated in me-
tastases, but then reverted to levels observed in the par-
ental mammary tumors when liver metastases were
collected and regrown in the mammary gland (Fig. 6b).
When twofold change cutoff rules were applied, there
were 54, 53, 123, and 19 genes within HCI01, HCI09,
UCD52, and WHIM2, respectively, that fit this
microenvironment-induced pattern. In contrast, within
the UCD52 PDX that was selected for liver-tropism, 810
genes were found to be upregulated at least twofold in
liver metastases, and they remained highly expressed
when the metastatic cells were collected and regrown in
the mammary gland (Fig. 6c); there were 18, 59, and 35
genes, for HCI01, HCI09, and WHIM2, respectively, that
were permanently upregulated after metastasis selection.
Collectively, these results provide evidence that clonal
selection of cells most fit to survive in organ microenvi-
ronments occurs and that the microenvironment in-
duces temporary genomic changes in the cancer cells.
Genetic signatures activated in basal-like metastases
Since every tumor has some variability in baseline gene




Fig. 5 Identification of genes within human metastasis signatures
that originate from liver cells. a RNA-seq data from patient-matched
breast tumors and liver metastases were downloaded from Siegel et
al. [30], median centered, and hierarchically clustered. Highlighted in
the purple box are 171 genes increased in each liver metastasis
compared to the primary tumor it was derived from. b ANOVA was
performed on the PDX mouse RNA-seq dataset for all 171 genes to
identify the transcripts which were induced in the liver cell
transcriptome during PDX metastasis compared to normal mouse
liver. Twenty-four liver genes were identified as significantly
upregulated (p < 0.05) in metastases compared to normal liver
and were averaged to generate a signature value for each
sample. PDX liver macro-metastases were used for the analyses
that had human RNA content > 50% (n = 19), normal mouse liver
(n = 3). c 27 liver relapses and 17 breast relapse fine-needle aspirates
from Tobin et al. [31] were queried for the 27-gene liver
microenvironment gene signature presented in Additional file 7c
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whether broader biological pathway analyses would reveal
genomic programs shared by basal-like PDXs when they
metastasize. Therefore, single-sample Gene Set Enrich-
ment Analysis was performed with 18,026 gene sets from
the Molecular Signatures Database. Hierarchical clustering
of the enrichment scores for each sample revealed that
every PDX was unique, and the metastases had a strong
correlation with mammary tumors (Fig. 7a). Shown in
Fig. 7b are the 416 gene sets that had higher enrichment
scores in basal-like liver and lung metastases compared to
mammary tumors. To identify the “sum of enrichment
scores” value, the difference in enrichment scores between
tumors and metastases for all six basal-like PDXs were
added together. The GAUTSCHI_SRC_SIGNALING gene
set [45] was found to be the most activated in metastases
across all the PDXs (Fig. 7c); the top two additional path-
ways that shared overlapping genes with this gene set in-
clude KEGG_TGF_BETA_SIGNALING_PATHWAY and
PLASARI_TGFB1_TARGETS_1HR_UP. Both these signa-
tures had higher enrichment scores in metastases com-
pared to mammary tumors (in 5 of 6 basal-like PDXs). To
determine if targeting SRC signaling would have cytotoxic
effects on the PDXs, spheroids were generated from mam-
mary tumors and treated with 3 SRC inhibitors. Each in-
hibitor exhibited cytotoxic activity on the basal-like
models (Fig. 7d) which provide justification for further in
vivo testing in the metastatic setting. However, since SRC
inhibitors have thus far failed as single agents for TNBC
[46, 47], our ongoing efforts are aimed at identifying syn-
ergistic combinations with SRC inhibitors and other drugs
to test on metastases.
Discussion
We sought to use PDX models to determine how organ
microenvironments change in parallel to cancer transcrip-
tomic variations during metastasis. The ability to separate
the PDX RNA-seq data into human (cancer) and mouse
(microenvironment) transcriptomic datasets allowed for a
clearer understanding of how each tissue compartment
contributes to gene profiles associated with metastatic
growth. Analysis of the cancer genomic data identified >




Fig. 6 Identification of microenvironment-regulated genes or metastasis-selected genes. a Approach used to compare gene expression profiles of
mammary gland tumors (MGT), liver metastases, and MGT which were grown from liver metastases. b Human ID1 gene expression levels in MGT,
metastases, and MGT grown from metastases. Most metastases have increased ID1 expression, which reverts to levels observed in parental MGT
when the metastases are collected and regrown in the mammary gland. c Shown are examples of genes upregulated in UCD52 liver metastases,
which maintained high expression when the liver metastases were collected and grown in the mammary gland
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metastases from most or all the basal-like PDXs. In
2015, Lawson et al. utilized the HCI01, HCI02, and
HCI10 PDXs and demonstrated that each PDX could
generate lung metastases from a mammary tumor
[48]; at the transcriptional level, the early metastatic
cells possessed a distinct stem-like gene expression
signature, whereas high-burden metastases became
more similar to the primary tumor. We also observed
many stem-cell, epithelial-to-mesenchymal transition,
and TGF-beta-related signatures being some of the
gene signatures most highly upregulated in the metas-
tases. We did note that when attempting to identify
genomic differences in primary tumors and micro- or
macro-metastases, the analyses could be influenced by
differences in the metastases themselves, fluctuating
proportions of transitory cells, as well as the read
depth of the sequencing. The extent or depth of se-
quencing per sample has been shown to be negatively
correlated with the robustness of differential gene
expression detection [49], and the average false dis-
covery rate of differently expressed genes increases as
read depth decreases. This implies that the higher the
read depth the more robust a differently expressed
gene list will be, especially for genes expressed at a
relatively low level. For PAM50 subtyping, we found
that at least 10M reads were ideal for tumor classifi-
cation. Some of the smaller micrometastasis samples
analyzed contained low human read counts; however,
due to limited numbers of samples for each PDX, for
some contrasts, we chose to utilize all data for DE
analysis. Moving forward, single-cell level information
will become important to analyze and contrast with
genomic insights from bulk tissue studies.
The genomic response of the liver microenvironment
cells in response to the cancer cells was similar for the
majority of the basal-like PDXs. The inflammatory re-
sponse gene profile was due in part to recruited S100A9





Fig. 7 Gene Set Enrichment Analyses identify signatures upregulated in metastases. a Gene set enrichment scores for tumors and metastases
were identified for 18,026 gene signatures and hierarchical clustered. b > 400 gene sets were found to be upregulated on average in metastases
from all six basal-like PDXs, the sum of enrichment scores was identified by adding together the difference in enrichment scores of all 6 PDXs
(metastases compared to tumors). c Average enrichment score values for one gene set across different tumors and metastases. d Effect of
targeting the most upregulated pathway with three different Src inhibitors on viability of PDX spheroids in suspension culture
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for metastasis [44, 50]. It is likely that some of the bio-
logical pathways activated within the metastatic micro-
environment could be non-invasively screened for in
blood samples from breast cancer patients as a
non-invasive assessment for initiation or growth of a
breast cancer liver metastasis; examples of secreted liver
factors that were upregulated in response to metastases
include NPY, VGF, SCG5, and CXCL1.
Biopsies of metastases are now being utilized to guide
therapeutic selection. The data we present in this study
revealed that 14% of a metastasis signature obtained
from human liver metastases were genes that were acti-
vated in the liver microenvironment in response to can-
cer invasion. A second human metastasis genetic dataset
also confirmed the influence of the microenvironment
on cancer genomic profile. Therefore, as we seek to de-
velop therapeutics that target both the cancer cells and
the microenvironment, these data, and more broadly
these approaches, can be used to determine the path-
ways in both tissue compartments that mediate viability.
Src signaling was identified as highly activated in metas-
tases; however, clinically, these inhibitors have failed to
prove effective as monotherapies and often lead to
tumor reprogramming to continue growing. Therefore,
we hypothesize that the best anti-metastasis therapies
will be synergistic drug combinations that target SRC in
addition to other metastasis-promoting programs identi-
fied in these studies.
Conclusions
In this set of studies, we sought to increase our un-
derstanding of the genomic programs that contribute
to successful breast cancer metastasis. Since the
growth of metastatic cells depends on the characteris-
tics of the cancer cells, as well as the response of the
organ being colonized, we aimed to elucidate parallel
mechanisms from both tissue compartments. Through
various experimental and computational approaches
using human tumors within immunocompromised
mice, the lung was found to be the most common
site of relapse; lymph nodes and liver were the other
most common metastatic sites. The majority of a
PDX genomic profile was maintained when the PDX
was growing in the liver, lung, or brain, yet common
genetic programs were identified that were activated
in the metastatic setting; targeting of this pathway
with Src inhibitors resulted in cytotoxicity to the
basal-like PDX spheroids. Multiple pathways within
the cancer cells, and potentially within the host organ
as well, may need to be targeted to inhibit the growth
of metastases. The consistent response by the micro-
environment highlights that this tumor compartment
warrants more attention for anti-metastasis therapy.
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